Replimune Group, Inc. (NASDAQ:REPL) Shares Purchased by Barclays PLC

Barclays PLC lifted its stake in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 165.5% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 158,491 shares of the company's stock after buying an additional 98,791 shares during the quarter. Barclays PLC owned approximately 0.23% of Replimune Group worth $1,738,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in REPL. Charles Schwab Investment Management Inc. increased its position in shares of Replimune Group by 12.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 484,797 shares of the company's stock valued at $5,313,000 after purchasing an additional 52,498 shares during the last quarter. LMR Partners LLP increased its holdings in Replimune Group by 145.8% in the third quarter. LMR Partners LLP now owns 82,479 shares of the company's stock valued at $904,000 after buying an additional 48,920 shares during the last quarter. Millennium Management LLC raised its stake in Replimune Group by 575.1% in the second quarter. Millennium Management LLC now owns 3,118,035 shares of the company's stock valued at $28,062,000 after buying an additional 2,656,173 shares in the last quarter. Cubist Systematic Strategies LLC lifted its holdings in Replimune Group by 282.2% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 72,207 shares of the company's stock worth $650,000 after buying an additional 53,313 shares during the last quarter. Finally, Acadian Asset Management LLC boosted its position in shares of Replimune Group by 63.2% during the 2nd quarter. Acadian Asset Management LLC now owns 185,516 shares of the company's stock worth $1,668,000 after acquiring an additional 71,867 shares in the last quarter. 92.53% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on REPL. BMO Capital Markets boosted their target price on Replimune Group from $14.00 to $18.00 and gave the stock an "outperform" rating in a research note on Friday, November 22nd. HC Wainwright reaffirmed a "buy" rating and issued a $17.00 target price on shares of Replimune Group in a research report on Friday, November 22nd. Jefferies Financial Group upped their price objective on shares of Replimune Group from $16.00 to $19.00 and gave the company a "buy" rating in a research note on Wednesday, December 4th. Finally, JPMorgan Chase & Co. boosted their target price on Replimune Group from $14.00 to $17.00 and gave the company an "overweight" rating in a report on Tuesday, September 24th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $17.29.

Replimune Group Stock Performance

Shares of NASDAQ REPL traded down $0.53 during midday trading on Friday, reaching $12.26. 383,045 shares of the company were exchanged, compared to its average volume of 1,043,153. The stock has a fifty day simple moving average of $12.39 and a 200 day simple moving average of $10.88. The company has a current ratio of 10.11, a quick ratio of 10.11 and a debt-to-equity ratio of 0.18. The stock has a market cap of $838.79 million, a P/E ratio of -4.02 and a beta of 1.26. Replimune Group, Inc. has a 1 year low of $4.92 and a 1 year high of $17.00.

Replimune Group (NASDAQ:REPL - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.75) by $0.07. On average, research analysts forecast that Replimune Group, Inc. will post -2.91 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Sushil Patel sold 10,000 shares of the stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $12.42, for a total transaction of $124,200.00. Following the completion of the transaction, the chief executive officer now directly owns 202,014 shares of the company's stock, valued at approximately $2,509,013.88. This represents a 4.72 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Konstantinos Xynos sold 7,246 shares of Replimune Group stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $10.78, for a total transaction of $78,111.88. Following the sale, the insider now owns 109,885 shares of the company's stock, valued at approximately $1,184,560.30. The trade was a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 8.80% of the stock is owned by insiders.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.